Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Home
/
update
/
details

QIAGEN and Illumina Unveil New Solutions to Advance Liquid Biopsy and Next-Generation Sequencing

NextEdge Admin

15 Oct 2024

3 min 13 sec

QIAGEN Introduces Key Enhancements to Liquid Biopsy Technologies for Advanced Biomarker Detection

QIAGEN has announced key updates to its sample technologies for non-invasive liquid biopsy applications in fields such as oncology, prenatal care, and organ transplantation. These enhancements include upgraded kits and platforms designed to improve biomarker detection through higher yields of circulating cell-free DNA (ccfDNA).

The enhanced EZ1&2 ccfDNA Kit now supports fully automated processing of 24 samples with up to 10 mL of serum or plasma, alongside a new urine protocol, addressing the need for larger sample inputs essential for low-frequency mutation detection. Additionally, the QIAsymphony DSP Circulating DNA Kits—available in standard and high-throughput versions—offer flexible solutions for labs of varying sizes, ensuring compliance with CE-IVDR and FDA regulations.

These updates expand QIAGEN’s automated solutions portfolio, enabling laboratories to perform high-sensitivity downstream analyses such as NGS, dPCR, and real-time PCR. Complementing these advancements is the new PAXgene Urine Liquid Biopsy Set, enhancing cfDNA analysis from urine samples.

Illumina Launches MiSeq™ i100 Series to Accelerate and Simplify Next-Generation Sequencing

Illumina, has introduced the MiSeq™ i100 Series, featuring the MiSeq i100 and MiSeq i100 Plus Systems, designed to simplify and accelerate next-generation sequencing (NGS) for labs. These benchtop instruments offer easy operation, room-temperature reagent storage, and same-day sample-to-analysis, making NGS more accessible, even for users with limited expertise.

The MiSeq i100 Series builds on the original MiSeq platform while incorporating advanced XLEAP-SBS™ chemistry and technology from the NovaSeq™ X Series. It offers two configurations: the i100 Plus with 100 million reads per run and the i100 with 25 million reads per run. Key features include faster run times (as short as four hours), reduced packaging waste by 85%, and cost-effective consumables.

Push-button workflows support applications like microbiology, oncology, and infectious disease, with real-time metrics available on the instrument or via cloud-based DRAGEN™ analysis. This compact, sustainable system delivers the speed, scalability, and ease required to advance genomic research.